The size of the MEA Respiratory Monitoring Devices market is estimated to reach USD 1.61 billion by 2027 from a market value of USD 1.20 billion in 2022, at a CAGR of 6.07%.
Respiratory Monitoring Devices are used to measure the amount of air we inhale or exhale, the Amount of oxygen present in the blood, or the amount of carbon dioxide.
Home care is expected to gain a substantial portion of the MEA respiratory monitoring devices market during the forecast period, increasing the number of industry companies gaining FDA clearance for home use respiratory monitoring devices.
The rising incidence of respiratory disorders in the Middle East and Africa, increasing healthcare spending per capita, a decreased unemployment rate, and a rise in the number of smokers are primarily boosting the growth rate of the respiratory monitoring devices market in the MEA region. Furthermore, due to the expanding geriatric population and improved public knowledge of advanced treatments, the Middle East and Africa are likely to have a moderate share in the global market during the forecast period.
The elderly population in the MEA is growing at a healthy pace, which has resulted in an increase in respiratory illnesses and a demand for respiratory equipment devices for monitoring the respiratory system during the forecast period. Asthma is one of the most significant contributors to this market, impacting children, adults, and the elderly. As a result, demand for Peak flow meters has increased, and this device is now the most dominant product in the respiratory monitoring market for the forecast period.
Other than the above, rising healthcare expenditure, growing expansion of advanced technologies, availability of low-cost respiratory monitoring devices, increasing geriatric population across the Middle East and Africa, increasing chronic obstructive pulmonary disease (COPD), Asthma, and tuberculosis patients, and high incidence of tobacco smoking and respiratory diseases are expected to respiratory monitoring devices market in this region.
However, high costs associated with COPD treatment and existing technologies are key factors that are expected to limit the market's growth during the forecast period. Furthermore, rising pollution levels and a rise in tobacco smoking are hastening the market's expansion. The most significant disadvantage of the monitoring devices is that unhealthy lifestyles and behaviors such as smoking may affect the respiratory process and harm the lungs.
This research report on the MEA respiratory monitoring devices market has been segmented and sub-segmented into the following categories:
By Diagnostic Devices:
By Monitoring Devices:
During the forecast period, the respiratory monitoring devices market in the Middle East and Africa is projected to account for a moderate share in the global market. Regulatory agencies such as the Medicines and Healthcare Products Regulatory Agency (MRHA) in the UAE and Kuwait control and monitor respiratory devices to prevent incidents and guarantee safe and have the fewest adverse responses. Therefore, the market for respiratory monitoring devices may be impacted by these strict licensing processes and regulatory policies.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the respiratory monitoring devices market in the MEA region profiled in this report are Covidien GE Healthcare, Philips Healthcare, Siemens Healthcare, Resmed, Merck & Co. Inc, Calondo Pharmaceuticals Inc., Quark Pharmaceuticals Inc., Access Pharmaceuticals Inc., Sirnaomics Inc., and Traversa Therapeutics Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]